SNGX Stock Summary and Trading Ideas (Soligenix | NASDAQ:SNGX)

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Soligenix trades on the NASDAQ stock market under the symbol SNGX.

As of April 2, 2026, SNGX stock price declined to $1.14 with 218,663 million shares trading.

SNGX has a beta of 0.12, meaning it tends to be less sensitive to market movements. SNGX has a correlation of 0.00 to the broad based SPY ETF.

SNGX has a market cap of $11.50 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, SNGX traded as high as $67.20 and as low as $1.00.

The top ETF exchange traded funds that SNGX belongs to (by Net Assets): VXF.

SNGX has underperformed the market in the last year with a price return of -48.4% while the SPY ETF gained +17.5%. SNGX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -19.7% and -6.6%, respectively, while the SPY returned -3.7% and -0.1%, respectively.

SNGX support price is $1.09 and resistance is $1.21 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SNGX shares will trade within this expected range on the day.